Actively Recruiting
Data Gathering for A10900 Using Optical Coherence Tomography in Retinal, Glaucoma, Corneal Diseases and Healthy Eyes
Led by Optos, PLC · Updated on 2026-02-13
180
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are collecting Optical Coherence Tomography (OCT) data to study both normal and diseased eyes, including conditions such as retinal disease, glaucoma, and corneal disease. This observational study aims to gather detailed imaging information to better understand these eye conditions using the A10900 OCT device. Participants will undergo OCT imaging with the A10900 device, which captures detailed pictures of the eye's structures. The study includes groups with retinal disease, glaucoma, corneal disease, and healthy eyes. Each participant will have OCT scans taken to collect data relevant to their specific eye condition or normal eye status. During the study, participants will have their eyes scanned with OCT and may undergo vision tests like best-corrected visual acuity (BCVA). Researchers will count the number of OCT scans performed over one year to measure outcomes. Participants will be monitored for their ability to tolerate imaging and comply with study procedures. The study includes healthy volunteers and people with various eye diseases, with ongoing safety and imaging quality assessments.
CONDITIONS
Brief Title
Data Gathering for A10900
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be 22 years of age or older at the time of consent
- Able to understand and willing to sign the informed consent
- For retinal disease group: diagnosed with retinal pathology such as macular degeneration, diabetic retinopathy, macular hole, or epiretinal membrane
- For glaucoma group: history of glaucomatous optic nerve damage and visual field defects within the past year
- For corneal group: diagnosed with corneal disease including disorders from contact lens use, post-refractive surgery, dry eye, or keratoconus
- For normal group: normal eyes with visual acuity 20/40 or better and no major posterior pole pathology
- Able to tolerate ophthalmic imaging and comply with study procedures
You will not qualify if you...
- Unable to tolerate ophthalmic imaging
- Unable to obtain acceptable OCT images due to ocular media opacity or other reasons
- Conditions or situations posing significant risk or interfering with study participation as judged by investigator
- For retinal disease group: presence of glaucoma or other ocular pathologies besides retinal disease
- For glaucoma group: no reliable visual field test result within the past year or ocular pathology other than glaucoma
- For corneal group: ocular media not clear enough for OCT imaging
- For normal group: history of leukemia, dementia, or multiple sclerosis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 1 year
Participants undergo imaging with the A10900 optical coherence tomography device to gather data on retinal, glaucoma, corneal diseases, or healthy eyes.
1 to 2 visits depending on disease group
Trial Site Locations
Total: 4 locations
1
Ketchum Health
Anaheim, California, United States, 92807
Actively Recruiting
2
Eye Disease Consultants, LLC
West Hartford, Connecticut, United States, 06107
Actively Recruiting
3
Eye Care and Laser Surgery of Newton Wellselley
Wellesley Hills, Massachusetts, United States, 02481
Completed
4
Charles Retina Institute
Germantown, Tennessee, United States, 38138
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here